Mohammad Allahtavakoli

Mohammad Allahtavakoli

Auto-generated profile, based on publicly available information

Mohammad Allahtavakoli

Physiology-Pharmacology Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

9 May 2015 in Basic & Clinical Pharmacology & Toxicology
Verified
Journal Article
Closed access
PDF file
MAMohammad Allahtavakoli
Mohammad Allahtavakoli
FAFatemeh Amin
Fatemeh Amin
AEAli Esmaeeli-Nadimi
Ali Esmaeeli-Nadimi
ASAli Shamsizadeh
Ali Shamsizadeh
MKMohammad Kazemi-Arababadi
Mohammad Kazemi-Arababadi
DKDerek Kennedy
Derek Kennedy

1 January 2017 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
GBGholamreza Bazmandegan
Gholamreza Bazmandegan
MBMohammad Taher Boroushaki
Mohammad Taher Boroushaki
ASAli Shamsizadeh
Ali Shamsizadeh
FAFatemeh Ayoobi
Fatemeh Ayoobi
EHElham Hakimizadeh
Elham Hakimizadeh
MAMohammad Allahtavakoli
Mohammad Allahtavakoli

1 September 2017 in Behavioural Brain Research
Verified
Journal Article
Closed access
EKElham Kaviani
Elham Kaviani
MRMohammadreza Rahmani
Mohammadreza Rahmani
AKAyat Kaeidi
Ayat Kaeidi
ASAli Shamsizadeh
Ali Shamsizadeh
MAMohamad Allahtavakoli
Mohamad Allahtavakoli
IFIman Fatemi
Iman Fatemi

1 February 2010 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
MRMohammad Ebrahim Rezvani
Mohammad Ebrahim Rezvani
ARAli Roohbakhsh
Ali Roohbakhsh
MAMohammad Allahtavakoli
Mohammad Allahtavakoli
ASAli Shamsizadeh
Ali Shamsizadeh

1 April 2012 in Stroke
Verified
Journal Article
Closed access
MSMunehisa Shimamura
Munehisa Shimamura
YTYoshiaki Taniyama
Yoshiaki Taniyama
NKNaruto Katsuragi
Naruto Katsuragi
NKNobutaka Koibuchi
Nobutaka Koibuchi
MKMariko Kyutoku
Mariko Kyutoku
RMRyuichi Morishita
Ryuichi Morishita
Background and Purpose—: Although periostin, an extracellular matrix glycoprotein, plays pivotal roles in survival, migration, and regeneration in various cells, its expression and function in the brain are still unknown. Here, we investigated the expression and role of periostin in the ischemic brain. Methods—: Expression of full-length periostin (periostin 1 [Pn1]) and its splicing variant lacking exon 17 (periostin 2 [Pn2]) was examined by real-time reverse transcription polymerase chain reaction (RT-PCR), Western blotting, and immunohistochemical staining in male C57BL6/J mice. The actions of periostin were examined in adult primary neuronal culture and in a transient middle cerebral artery occlusion (tMCAo) model. Results—: Expression of Pn2, but not of Pn1, mRNA was markedly changed after tMCAo. Pn2 mRNA was decreased in the ischemic core at 3 hours after ischemia. At 24 hours, Pn2 mRNA was significantly increased in both the peri-ischemic and ischemic regions. Periostin was mainly observed in neurons in normal brain. However, neuronal expression of periostin was decreased temporarily in the ischemic region, but increased in astrocytes and around endothelial cells at 24 hours after tMCAo. Of importance, intracerebroventricular injection of Pn2 resulted in a significant reduction in infarct volume at 24 hours after tMCAo associated with phosphorylation of Akt. Also, the Pn2-treated mice survived longer until 1 week after tMCAo. Pn2 significantly inhibited neuronal death under hypoxia and stimulated neurite outgrowth. Conclusions—: Here, we demonstrated that periostin was expressed in the brain, and exogenous Pn2 exhibited neuroprotective effects and accelerated neurite outgrowth. Additional studies on periostin may provide new insights into the treatment of ischemic stroke.